NASDAQ: LGND

Pfizer announced the commercial launch of Cejemly (sugemalimab) in China for Stage III non-small cell lung cancer (NSCLC), marking the PD-L1 inhibitor’s second approved indication in the country. The therapy, developed by CStone Pharmaceuticals (HKG: 2616) under a license from Ligand Pharmaceuticals (NASDAQ: LGND), is now the only immunotherapy approved…